Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study.

Acadia Pharmaceuticals Inc. headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $136.4B in funding across 168 round(s). With a team of 501-1000 employees, Acadia Pharmaceuticals Inc. is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Acadia Pharmaceuticals Inc., raised $15.0M. Discover more about their projects, partnerships, and impact on our platform.